0000000000633950

AUTHOR

Katrīna Bandere

showing 3 related works from this author

A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®

2019

Patient: Male, 59 Final Diagnosis: Chromophobe renal cell carcinoma, stage IV Symptoms: Discomfort in the right hypochondrium Medication: Oncolytic virus Rigvir Clinical Procedure: Nephro-adrenalectomy Specialty: Oncology Objective: Unusual or unexpected effect of treatment Background: Renal cell carcinoma is the most commonly diagnosed primary malignant tumor of the kidney in adults, and includes the variant of chromophobe renal cell carcinoma. Despite new targeted therapies that improve progression-free survival (PFS) and overall survival (OS) for early-stage renal cell carcinoma, the 5-year survival for patients with stage IV renal cell carcinoma remains below 10%, and the 50% OS is less…

Malemedicine.medical_specialtymedicine.medical_treatmentChromophobe Renal Cell CarcinomaAdrenal Gland NeoplasmsUrology030204 cardiovascular system & hematologyNephrectomyVirus03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineCarcinomaHumansCarcinoma Renal CellOncolytic VirotherapyKidneybusiness.industryAdrenalectomyAdrenalectomyArticlesGeneral MedicineMiddle Agedmedicine.diseaseKidney NeoplasmsNephrectomyEnterovirus B HumanOncolytic virusOncolytic Virusesmedicine.anatomical_structure030220 oncology & carcinogenesisbusinessAmerican Journal of Case Reports
researchProduct

Initiation of Vancomycin Therapy and the First Therapeutic Drug Monitoring

2021

Abstract There have been a limited number of studies in Latvia that were focused on vancomycin therapeutic drug monitoring (TDM), especially during the initiation phase of the therapy. The aim of this study was to investigate details of vancomycin therapy in its initiation phase and to analyse the results of the first therapeutic drug monitoring within a multidisciplinary hospital in Latvia. A retrospective observational study was performed in a multidisciplinary hospital in Latvia. Adult patients hospitalised in an intensive care unit and undergoing vancomycin therapy with at least one concentration measurement were included in this study. Data about patients included demographic and clini…

0301 basic medicinenarrow therapeutic rangeMultidisciplinaryGeneral interestmedicine.diagnostic_testconcentration measurementScience030106 microbiologyQantibacterial agentsPharmacologyminimum inhibitory concentrationVancomycin therapy03 medical and health sciencesMinimum inhibitory concentration0302 clinical medicineTherapeutic drug monitoringmedicine030212 general & internal medicineProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Trombocitozes saistība ar ne-sīkšūnu plaušu vēža pacientu demogrāfiskajiem un klīniskajiem faktoriem

2019

Ievads. Lai gan tiek izstrādātas arvien efektīvākas ļaundabīgo audzēju agrīnas skrīninga un diagnostikas metodes, ne-sīkšūnu plaušu vēzis vēl joprojām pārsvarā tiek atklāts III vai IV stadijā, līdz ar to tas ir viens no vadošajiem audzējiem mirstības ziņā. Trombocīti piedalās vēža šūnu augšanā un tālākā izplatīšanā pa organismu. Ne-sīkšūnu plaušu vēža pacientiem bieži ir palielināts trombocītu skaits, kas ir saistīts ar sliktu prognozi. Tamdēļ, ir būtiski noskaidrot vai pastāv kādi ne-sīkšūnu plauša vēža pacienta demogrāfiskie vai klīniskie rādītāji, kam ir korelācija ar trombocitozi. Tas ļautu laicīgi paredzēt to, ka pacientam iespējams būs palielināts trombocītu skaits un izrietoši sliktā…

trombocitozene-sīkšūnu plaušu vēzisthrombocytosisnon-small cell lung cancerMedicīna
researchProduct